Login / Signup

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.

Barbara KiesewetterNathan I ChernyNicolas BoisselFrancesco CerisoliUrania DafniElisabeth G E de VriesPaolo GhiaNicola GökbugetVerónica González-CalleBrian HuntlyUlrich JägerNicola Jane LatinoJean-Yves DouillardLuca MalcovatiMaría-Victoria MateosGert J OssenkoppeleKimmo PorkkaMarkus RadererJosep-Maria RiberaLydia ScarfòRuth WesterPanagiota ZygouraPieter Sonneveld
Published in: ESMO open (2021)
Based on the findings of this study, ESMO and EHA are committed to develop a version of the ESMO-MCBS that is validated for haematological malignancies. This development process will incorporate all of the usual stringencies for accountability of reasonableness that have characterised the development of the ESMO-MCBS including field testing, statistical modelling, evaluation for reasonableness and openness to appeal and revision. Applying such a scale will support future public policy decision-making regarding the value of new treatments for haematological malignancies and will provide insights that could be helpful in the design of future clinical trials.
Keyphrases
  • clinical trial
  • decision making
  • healthcare
  • current status
  • mental health
  • public health
  • total knee arthroplasty
  • emergency department
  • randomized controlled trial
  • open label
  • total hip arthroplasty
  • double blind